These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19647079)

  • 21. Tolerability of ziprasidone: an expanding perspective.
    Daniel DG
    J Clin Psychiatry; 2003; 64 Suppl 19():40-9. PubMed ID: 14728089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Bae KY; Yang SJ; Yoon JS
    Clin Neuropharmacol; 2010 May; 33(3):121-5. PubMed ID: 20502130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Scott LJ
    CNS Drugs; 2006; 20(12):1027-52. PubMed ID: 17140281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service.
    Kohen I; Preval H; Southard R; Francis A
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):240-5. PubMed ID: 16503319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
    Zimbroff D; Warrington L; Loebel A; Yang R; Siu C
    Int Clin Psychopharmacol; 2007 Nov; 22(6):363-70. PubMed ID: 17917555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Ratner Y; Gibel A; Yorkov V; Ritsner MS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A twenty-four-week, open-label study on ziprasidone's efficacy and influence on glucolipid metabolism in patients with schizophrenia and metabolic disorder.
    Li CH; Shi L; Zhan GL; Rao SZ; Zhang H
    Eur Rev Med Pharmacol Sci; 2013 Aug; 17(16):2136-40. PubMed ID: 23893178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
    Olié JP; Spina E; Murray S; Yang R
    Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia.
    Arango C; Gómez-Beneyto M; Brenlla J; Gastó C; Sarramea-Crespo F; Chamorro L; Masramon X; Díez T;
    Eur Neuropsychopharmacol; 2007; 17(6-7):456-63. PubMed ID: 17234389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.
    Daniel DG; Zimbroff DL; Potkin SG; Reeves KR; Harrigan EP; Lakshminarayanan M
    Neuropsychopharmacology; 1999 May; 20(5):491-505. PubMed ID: 10192829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug safety evaluation of ziprasidone.
    Citrome L
    Expert Opin Drug Saf; 2011 May; 10(3):437-48. PubMed ID: 21332416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Practical aspects of the use of ziprasidone in schizophrenia].
    Ochedzan D; Jarema M
    Psychiatr Pol; 2010; 44(6):881-93. PubMed ID: 21449170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term safety of ziprasidone in schizophrenic patients: an open trial.
    Sciarretta A; Piazzi G
    Eur Rev Med Pharmacol Sci; 2012 Dec; 16(15):2113-9. PubMed ID: 23280028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switching among antipsychotics in everyday clinical practice: focus on ziprasidone.
    Rossi A; Cañas F; Fagiolini A; Larmo I; Levy P; Montes JM; Papageorgiou G; Sturlason R; Zink M; Correll CU
    Postgrad Med; 2011 Jan; 123(1):135-59. PubMed ID: 21293094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Question regarding ziprasidone and QTc interval prolongation in the ZODIAC study.
    Vieweg WV; Hasnain M
    Am J Psychiatry; 2011 Jun; 168(6):650-1; author reply 651. PubMed ID: 21642483
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder.
    Mandrioli R; Protti M; Mercolini L
    Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):149-74. PubMed ID: 25483358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ziprasidone as a possible cause of cleft palate in a newborn.
    Peitl MV; Petrić D; Peitl V
    Psychiatr Danub; 2010 Mar; 22(1):117-9. PubMed ID: 20305605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
    Zink M; Kuwilsky A; Krumm B; Dressing H
    J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study.
    Goff DC; McEvoy JP; Citrome L; Mech AW; Bustillo JR; Gil R; Buckley P; Manschreck TC; Achtyes ED; Macklin EA
    J Clin Psychopharmacol; 2013 Aug; 33(4):485-90. PubMed ID: 23775057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case report with ziprasidone-induced catatonic symptoms.
    Markham-Abedi C; McNeely C; de Leon J
    J Neuropsychiatry Clin Neurosci; 2007; 19(4):476-7. PubMed ID: 18070860
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.